WAM
ESPR

Wolverine Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Wolverine Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-88,906
Closed -$236K – 1727
2025
Q3 		$236K Hold
88,906
– – ﹤0.01% 991
2025
Q2 		$87.5K Hold
88,906
– – ﹤0.01% 1143
2025
Q1 		$128K Buy
88,906
+1,522
+2% +$2.81K ﹤0.01% 1070
2024
Q4 		$192K Hold
87,384
– – ﹤0.01% 1031
2024
Q3 		$144K Hold
87,384
– – ﹤0.01% 1065
2024
Q2 		$194K Hold
87,384
– – ﹤0.01% 1002
2024
Q1 		$234K Hold
87,384
– – ﹤0.01% 938
2023
Q4 		$261K Hold
87,384
– – ﹤0.01% 1008
2023
Q3 		$85.6K Hold
87,384
– – ﹤0.01% 1165
2023
Q2 		$121K Hold
87,384
– – ﹤0.01% 1054
2023
Q1 		$139K Hold
87,384
– – ﹤0.01% 1071
2022
Q4 		$544K Sell
87,384
-57,861
-40% -$414K 0.01% 927
2022
Q3 		$973K Sell
145,245
-2,624
-2% -$18K 0.01% 797
2022
Q2 		$940K Sell
147,869
-1,732
-1% -$9.82K 0.01% 805
2022
Q1 		$694K Buy
149,601
+5,969
+4% +$25.6K 0.01% 882
2021
Q4 		$718K Buy
143,632
+28,432
+25% +$228K 0.01% 911
2021
Q3 		$1.39M Buy
115,200
+40,200
+54% +$585K 0.01% 614
2021
Q2 		$1.59M Buy
+75,000
New +$1.81M 0.01% 497

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wolverine Asset Management's ESPR Position: Q4 2025 in Review

Wolverine Asset Management sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 88,906 shares — an estimated $236K sold.

Wolverine Asset Management first reported a position in ESPR in Q2 2021 and held it in 18 quarters. The position peaked at $1.59M in Q2 2021. 201 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

  • Wolverine Asset Management reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wolverine Asset Management sold 88,906 Esperion Therapeutics shares in Q4 2025, an estimated $236K.
  • Wolverine Asset Management first reported a position in Esperion Therapeutics in Q2 2021 and held it in 18 quarters.
  • Wolverine Asset Management's Esperion Therapeutics position peaked at $1.59M in Q2 2021.
  • 201 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on Wolverine Asset Management's 13F filing for Q4 2025, filed 2 Feb 2026.